131 related articles for article (PubMed ID: 26181268)
1. Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps.
Cobain EF; Chinnaiyan AM; Kurzrock R; Baker LH
JAMA Oncol; 2015 Jul; 1(4):542. PubMed ID: 26181268
[No Abstract] [Full Text] [Related]
2. Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps.
Varghese AM; Saltz LB
JAMA Oncol; 2015 Jul; 1(4):541-2. PubMed ID: 26181267
[No Abstract] [Full Text] [Related]
3. Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps.
Whang YE; Hayes DN
JAMA Oncol; 2015 Jul; 1(4):541. PubMed ID: 26181266
[No Abstract] [Full Text] [Related]
4. Genomic Profiling of Cancers of Unknown Primary Site--Reply.
Ross JS; Miller VA; Stephens PJ
JAMA Oncol; 2015 Jul; 1(4):542-3. PubMed ID: 26181269
[No Abstract] [Full Text] [Related]
5. Carcinoma of Unknown Primary Site: The Poster Child for Personalized Medicine?
Varadhachary G
JAMA Oncol; 2015 Apr; 1(1):19-21. PubMed ID: 26182299
[No Abstract] [Full Text] [Related]
6. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling for CUP cancers: are we there yet?
Varadhachary G
Onkologie; 2012; 35(1-2):11-2. PubMed ID: 22310338
[No Abstract] [Full Text] [Related]
8. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
9. Cancer of Unknown Primary in the Molecular Era.
Kato S; Alsafar A; Walavalkar V; Hainsworth J; Kurzrock R
Trends Cancer; 2021 May; 7(5):465-477. PubMed ID: 33516660
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases.
Gatalica Z; Millis SZ; Vranic S; Bender R; Basu GD; Voss A; Von Hoff DD
Oncotarget; 2014 Dec; 5(23):12440-7. PubMed ID: 25415047
[TBL] [Abstract][Full Text] [Related]
11. An integrated tool for determining the primary origin site of metastatic tumours.
Santos MTD; Souza BF; Cárcano FM; Vidal RO; Scapulatempo-Neto C; Viana CR; Carvalho AL
J Clin Pathol; 2018 Jul; 71(7):584-593. PubMed ID: 29248889
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Carcinoma of Unknown Primary on Cytologic Specimens.
Doxtader EE; Chute DJ
Surg Pathol Clin; 2018 Sep; 11(3):545-562. PubMed ID: 30190140
[TBL] [Abstract][Full Text] [Related]
13. A primary approach to cancers of unknown primary.
Schwartz AM; Harpaz N
J Natl Cancer Inst; 2013 Jun; 105(11):759-61. PubMed ID: 23641044
[No Abstract] [Full Text] [Related]
14. Precision medicine: lessons learned from the SHIVA trial.
Weiss GJ
Lancet Oncol; 2015 Dec; 16(16):e580. PubMed ID: 26678199
[No Abstract] [Full Text] [Related]
15. Precision medicine: lessons learned from the SHIVA trial.
Hahn AW; Martin MG
Lancet Oncol; 2015 Dec; 16(16):e580-1. PubMed ID: 26678198
[No Abstract] [Full Text] [Related]
16. Precision medicine: lessons learned from the SHIVA trial.
Tsimberidou AM; Kurzrock R
Lancet Oncol; 2015 Dec; 16(16):e579-80. PubMed ID: 26678197
[No Abstract] [Full Text] [Related]
17. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.
Pal SK; Agarwal N; Boorjian SA; Hahn NM; Siefker-Radtke AO; Clark PE; Plimack ER
J Clin Oncol; 2016 Sep; 34(27):3346-8. PubMed ID: 27458279
[No Abstract] [Full Text] [Related]
18. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
Olivier T; Fernandez E; Labidi-Galy I; Dietrich PY; Rodriguez-Bravo V; Baciarello G; Fizazi K; Patrikidou A
Cancer Treat Rev; 2021 Jun; 97():102204. PubMed ID: 33866225
[TBL] [Abstract][Full Text] [Related]
19. Precision medicine: lessons learned from the SHIVA trial - Authors' reply.
Le Tourneau C; Belin L; Paoletti X; Bièche I; Kamal M
Lancet Oncol; 2015 Dec; 16(16):e581-2. PubMed ID: 26678200
[No Abstract] [Full Text] [Related]
20. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
Rassy E; Pavlidis N
Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
